RhumbLine Advisers’s Eledon Pharmaceuticals ELDN Stock Holding History

RhumbLine Advisers’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$223K	Sell	87,988 -621	-0.7%	-$2.09K	﹤0.01%	3209
2026 Q2	$349K	Buy	88,609 +40,983	+86%	+$149K	﹤0.01%	2979
2026 Q1	$147K	Buy	47,626 +3,009	+7%	+$7.09K	﹤0.01%	3253
2025 Q4	$67.4K	Sell	44,617 -8,947	-17%	-$21.3K	﹤0.01%	3581
2025 Q3	$139K	Sell	53,564 -2,486	-4%	-$7.27K	﹤0.01%	3388
2025 Q2	$152K	Buy	+56,050	New	+$168K	﹤0.01%	3375
2017 Q2	–	Sell	-197	Closed	-$27K	–	2932
2017 Q1	$27K	Buy	+197	New	+$28.9K	﹤0.01%	2838
2016 Q2	–	Sell	-70	Closed	-$64K	–	2992
2016 Q1	$64K	Buy	70 +3	+4%	+$2.94K	﹤0.01%	2949
2015 Q4	$94K	Buy	67 +5	+8%	+$8.71K	﹤0.01%	2962
2015 Q3	$104K	Buy	+62	New	+$128K	﹤0.01%	2940

Other funds holding ELDN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

AIC

AWM Investment Company New York $1.04B AUM 103.31% 1-Year Est. Return

22NW LP Seattle, Washington $144M AUM 2.58% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

RhumbLine Advisers's ELDN Position: Q3 2026 in Review

RhumbLine Advisers reduced its Eledon Pharmaceuticals (ELDN) stake by 0.7% in Q3 2026, selling an estimated $2.09K and leaving 87,988 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #3209.

RhumbLine Advisers first reported a position in ELDN in Q3 2015 and has held it in 10 quarters since. The position peaked at $349K in Q2 2026. 114 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

RhumbLine Advisers held 87,988 shares of Eledon Pharmaceuticals worth $223K as of Q3 2026.
RhumbLine Advisers sold 621 Eledon Pharmaceuticals shares in Q3 2026, an estimated $2.09K.
Eledon Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3209 holding.
RhumbLine Advisers first reported a position in Eledon Pharmaceuticals in Q3 2015 and has held it in 10 quarters since.
RhumbLine Advisers's Eledon Pharmaceuticals position peaked at $349K in Q2 2026.
114 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.